BioVie Inc. (BIVI)
NASDAQ: BIVI · Real-Time Price · USD
1.390
+0.110 (8.59%)
At close: Oct 9, 2026, 4:00 PM EDT
1.350
-0.040 (-2.88%)
After-hours: Oct 9, 2026, 7:04 PM EDT
BioVie Employees
BioVie had 13 employees as of June 30, 2026. The number of employees did not change compared to the previous year. That makes BioVie the 39,423rd largest employer in the world and 5,833rd in the United States.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,701,262
Market Cap
10.48M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 13 | 0 | - | 13 | 0 |
| Jun 30, 2025 | 13 | -1 | -7.14% | 13 | 0 |
| Jun 30, 2024 | 14 | -4 | -22.22% | 14 | 0 |
| Jun 30, 2023 | 18 | 5 | 38.46% | 18 | 0 |
| Jun 30, 2022 | 13 | 7 | 116.67% | 13 | 0 |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Vistagen Therapeutics | 41 |
| Senti Biosciences Holdings | 39 |
| Lantern Pharma | 16 |
| Theriva Biologics | 16 |
| Purple Biotech | 10 |
| Ensysce Biosciences | 10 |
| Immuron | 8 |
BIVI News
- 12 days ago - BioVie Proxy statement: Proxy filing - Filings
- 16 days ago - BioVie Transcript: Status update - Transcripts
- 25 days ago - BioVie Transcript: Study result - Transcripts
- 25 days ago - BioVie Press release: Study result - Filings
- 25 days ago - BioVie Slides: Study result - Filings
- 25 days ago - BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - GlobeNewsWire
- 25 days ago - BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid - GlobeNewsWire
- 4 weeks ago - BioVie Announces Update to Parkinson's Phase 3 Development Program - GlobeNewsWire